215 related articles for article (PubMed ID: 35436146)
1. Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia.
Chang A; Akhtar A; Linderman SL; Lai L; Orellana-Noia VM; Valanparambil R; Ahmed H; Zarnitsyna VI; McCook-Veal AA; Switchenko JM; Koff JL; Blum KA; Ayers AA; O'Leary CB; Churnetski MC; Sulaiman S; Kives M; Sheng P; Davis CW; Nooka AK; Antia R; Dhodapkar MV; Suthar MS; Cohen JB; Ahmed R
J Clin Oncol; 2022 Sep; 40(26):3020-3031. PubMed ID: 35436146
[TBL] [Abstract][Full Text] [Related]
2. Exposure of progressive immune dysfunction by SARS-CoV-2 mRNA vaccination in patients with chronic lymphocytic leukemia: A prospective cohort study.
Qin K; Honjo K; Sherrill-Mix S; Liu W; Stoltz RM; Oman AK; Hall LA; Li R; Sterrett S; Frederick ER; Lancaster JR; Narkhede M; Mehta A; Ogunsile FJ; Patel RB; Ketas TJ; Cruz Portillo VM; Cupo A; Larimer BM; Bansal A; Goepfert PA; Hahn BH; Davis RS
PLoS Med; 2023 Jun; 20(6):e1004157. PubMed ID: 37384638
[TBL] [Abstract][Full Text] [Related]
3. Antibody binding and neutralization of live SARS-CoV-2 variants including BA.4/5 following booster vaccination of patients with B-cell malignancies.
Chang A; Akhtar A; Lai L; Orellana-Noia VM; Linderman SL; McCook-Veal AA; Switchenko JM; Saini M; Valanparambil RM; Blum KA; Allen PB; Lechowicz MJ; Romancik JT; Ayers A; Leal A; O'Leary CB; Churnetski MC; Baird K; Kives M; Wrammert J; Nooka AK; Koff JL; Dhodapkar MV; Suthar MS; Cohen JB; Ahmed R
Cancer Res Commun; 2022 Dec; 2(12):1684-1692. PubMed ID: 36644323
[TBL] [Abstract][Full Text] [Related]
4. Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant.
Valanparambil RM; Carlisle J; Linderman SL; Akthar A; Millett RL; Lai L; Chang A; McCook-Veal AA; Switchenko J; Nasti TH; Saini M; Wieland A; Manning KE; Ellis M; Moore KM; Foster SL; Floyd K; Davis-Gardner ME; Edara VV; Patel M; Steur C; Nooka AK; Green F; Johns MA; O'Brein F; Shanmugasundaram U; Zarnitsyna VI; Ahmed H; Nyhoff LE; Mantus G; Garett M; Edupuganti S; Behra M; Antia R; Wrammert J; Suthar MS; Dhodapkar MV; Ramalingam S; Ahmed R
J Clin Oncol; 2022 Nov; 40(33):3808-3816. PubMed ID: 35759727
[TBL] [Abstract][Full Text] [Related]
5. Neutralizing antibody response against the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants after a third mRNA SARS-CoV-2 vaccine dose in kidney transplant recipients.
Benning L; Morath C; Bartenschlager M; Kim H; Reineke M; Beimler J; Buylaert M; Nusshag C; Kälble F; Reichel P; Töllner M; Schaier M; Klein K; Benes V; Rausch T; Rieger S; Stich M; Tönshoff B; Weidner N; Schnitzler P; Zeier M; Süsal C; Hien Tran T; Bartenschlager R; Speer C
Am J Transplant; 2022 Jul; 22(7):1873-1883. PubMed ID: 35384272
[TBL] [Abstract][Full Text] [Related]
6. Antibody response to SARS-CoV-2 mRNA vaccine in lung cancer patients: Reactivity to vaccine antigen and variants of concern.
Valanparambil R; Carlisle J; Linderman S; Akthar A; Millett RL; Lai L; Chang A; McCook A; Switchenko J; Nasti T; Saini M; Andreas Wieland AW; Manning K; Ellis M; Moore K; Foster S; Floyd K; Davis-Gardner M; Viswanadh Edara V; Patel M; Steur C; Nooka A; Green F; Johns M; O Brein F; Shanmugasundaram U; Zarnitsyna V; Ahmed H; Nyhoff L; Mantus G; Garett M; Edupuganti S; Behra M; Antia R; Wrammert J; Suthar M; Dhodapkar M; Ramalingam S; Ahmed R
medRxiv; 2022 Jan; ():. PubMed ID: 35018383
[TBL] [Abstract][Full Text] [Related]
7. Impaired Humoral Immunity to SARS-CoV-2 Vaccination in Non-Hodgkin Lymphoma and CLL Patients.
Diefenbach C; Caro J; Koide A; Grossbard M; Goldberg JD; Raphael B; Hymes K; Moskovits T; Kreditor M; Kaminetzky D; Fleur-Lominy SS; Choi J; Thannickal SA; Stapleford KA; Koide S
medRxiv; 2021 Jun; ():. PubMed ID: 34100025
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneous SARS-CoV-2-Neutralizing Activities After Infection and Vaccination.
Graninger M; Camp JV; Aberle SW; Traugott MT; Hoepler W; Puchhammer-Stöckl E; Weseslindtner L; Zoufaly A; Aberle JH; Stiasny K
Front Immunol; 2022; 13():888794. PubMed ID: 35711424
[TBL] [Abstract][Full Text] [Related]
9. Preserved recognition of Omicron spike following COVID-19 messenger RNA vaccination in pregnancy.
Bartsch YC; Atyeo C; Kang J; Cai Y; Chen B; Gray KJ; Edlow AG; Alter G
Am J Obstet Gynecol; 2022 Sep; 227(3):493.e1-493.e7. PubMed ID: 35430229
[TBL] [Abstract][Full Text] [Related]
10. Anti-CD20 antibodies and bendamustine attenuate humoral immunity to COVID-19 vaccination in patients with B-cell non-Hodgkin lymphoma.
Ishio T; Tsukamoto S; Yokoyama E; Izumiyama K; Saito M; Muraki H; Kobayashi M; Mori A; Morioka M; Kondo T
Ann Hematol; 2023 Jun; 102(6):1421-1431. PubMed ID: 37041299
[TBL] [Abstract][Full Text] [Related]
11. Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination.
Dapporto F; Marchi S; Leonardi M; Piu P; Lovreglio P; Decaro N; Buonvino N; Stufano A; Lorusso E; Bombardieri E; Ruello A; Viviani S; Molesti E; Trombetta CM; Manenti A; Montomoli E
J Immunol Res; 2022; 2022():4813199. PubMed ID: 36093434
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.
Taucher C; Lazarus R; Dellago H; Maurer G; Weisova P; Corbic-Ramljak I; Dubischar K; Lilja A; Eder-Lingelbach S; Hochreiter R; Jaramillo JC; Junker H; Krammer M; Pusic P; Querton B; Larcher-Senn J; Hoffmann M; Pöhlmann S; Finn A;
J Infect; 2023 Sep; 87(3):242-254. PubMed ID: 37406777
[TBL] [Abstract][Full Text] [Related]
13. Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2.
Xia H; Zou J; Kurhade C; Cai H; Yang Q; Cutler M; Cooper D; Muik A; Jansen KU; Xie X; Swanson KA; Shi PY
Cell Host Microbe; 2022 Apr; 30(4):485-488.e3. PubMed ID: 35245438
[TBL] [Abstract][Full Text] [Related]
14. Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine.
Gavriatopoulou M; Terpos E; Kastritis E; Briasoulis A; Gumeni S; Ntanasis-Stathopoulos I; Sklirou AD; Malandrakis P; Eleutherakis-Papaiakovou E; Migkou M; Trougakos IP; Dimopoulos MA
Clin Exp Med; 2022 May; 22(2):319-323. PubMed ID: 34283338
[TBL] [Abstract][Full Text] [Related]
15. Comparative analysis of the neutralizing activity against SARS-CoV-2 Wuhan-Hu-1 strain and variants of concern: Performance evaluation of a pseudovirus-based neutralization assay.
D'Apice L; Trovato M; Gramigna G; Colavita F; Francalancia M; Matusali G; Meschi S; Lapa D; Bettini A; Mizzoni K; Aurisicchio L; Di Caro A; Castilletti C; De Berardinis P
Front Immunol; 2022; 13():981693. PubMed ID: 36225911
[TBL] [Abstract][Full Text] [Related]
16. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
17. Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination.
Jalkanen P; Kolehmainen P; Haveri A; Huttunen M; Laine L; Österlund P; Tähtinen PA; Ivaska L; Maljanen S; Reinholm A; Belik M; Smura T; Häkkinen HK; Ortamo E; Kantele A; Julkunen I; Lempainen J; Kakkola L
Microbiol Spectr; 2022 Apr; 10(2):e0225221. PubMed ID: 35262410
[TBL] [Abstract][Full Text] [Related]
18. Multiple COVID-19 vaccine doses in CLL and MBL improve immune responses with progressive and high seroconversion.
Shen Y; Freeman JA; Holland J; Naidu K; Solterbeck A; Van Bilsen N; Downe P; Kerridge I; Wallman L; Akerman A; Aggarwal A; Milogiannakis V; Martins Costa Gomes G; Doyle CM; Sandgren KJ; Turville S; Cunningham AL; Mulligan SP
Blood; 2022 Dec; 140(25):2709-2721. PubMed ID: 36206503
[TBL] [Abstract][Full Text] [Related]
19. Functional humoral and cellular response of monovalent COVID-19-vaccines against Omicron BA.2 variant of SARS-CoV-2 in patients with chronic lymphocytic leukemia.
Passerini M; Ratishvili T; Monroe JM; Temesgen Z; Witzig TE; Kay NE; Kennedy RB; Parikh SA
Leuk Lymphoma; 2023 Apr; 64(4):874-883. PubMed ID: 36908110
[TBL] [Abstract][Full Text] [Related]
20. Immune Responses to SARS-CoV-2 Vaccination in Young Patients with Anti-CD19 Chimeric Antigen Receptor T Cell-Induced B Cell Aplasia.
Jarisch A; Wiercinska E; Huenecke S; Bremm M; Cappel C; Hauler J; Rettinger E; Soerensen J; Hellstern H; Klusmann JH; Ciesek S; Bonig H; Bader P
Transplant Cell Ther; 2022 Jul; 28(7):366.e1-366.e7. PubMed ID: 35472554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
